Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Decreases By 89.4%

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the recipient of a large drop in short interest during the month of November. As of November 15th, there was short interest totalling 42,000 shares, a drop of 89.4% from the October 31st total of 396,100 shares. Currently, 0.2% of the shares of the stock are sold short. Based on an average daily volume of 263,800 shares, the short-interest ratio is currently 0.2 days.

Xilio Therapeutics Price Performance

XLO opened at $1.01 on Thursday. Xilio Therapeutics has a fifty-two week low of $0.49 and a fifty-two week high of $1.93. The company has a market cap of $44.40 million, a price-to-earnings ratio of -0.59 and a beta of -0.24. The firm has a 50 day simple moving average of $0.93 and a 200 day simple moving average of $0.94.

Institutional Investors Weigh In On Xilio Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC increased its stake in Xilio Therapeutics by 18.3% in the second quarter. Renaissance Technologies LLC now owns 295,000 shares of the company’s stock valued at $280,000 after purchasing an additional 45,554 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Xilio Therapeutics in the 2nd quarter valued at $32,000. Finally, Geode Capital Management LLC raised its stake in Xilio Therapeutics by 85.0% during the 3rd quarter. Geode Capital Management LLC now owns 338,192 shares of the company’s stock worth $266,000 after buying an additional 155,337 shares during the period. 54.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Raymond James dropped their price objective on shares of Xilio Therapeutics from $6.00 to $4.00 and set an “outperform” rating for the company in a research report on Friday, November 8th.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.